FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* DEC TIMOTHY C				<u>S</u>	2. Issuer Name and Ticker or Trading Symbol SUPERNUS PHARMACEUTICALS, INC. [SUPN]					C. Cr	5. Relationship of Reporting Person(s) to Issu (Check all applicable) Director 10% Ow Officer (give title Other (st				ner	
	(Last) (First) (Middle) C/O SUPERNUS PHARMACEUTICALS, INC. 9715 KEY WEST AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 08/23/2021						X Officer (give title below) Unter (specify below) Senior Vice-President & CFO				·	
(Street) ROCKV (City)	ILLE M	D	20850 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Lin	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date			. Transactio ate Month/Day/Y	Execution Date,		Code (Ins 8)	on Dispose tr. 5)	'		Beneficia Owned F Reported Transact	es ally following d ion(s))		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									(D)		(Instr. 3	3 and 4)				
			Fable II - De (e.					uired, Dis s, options,				Owned				
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any		Code	ansaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Am of Securities Underlying Derivative Sect (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (Right to Buy)	\$25.09	08/23/2021		A		85,000		(1)	08/23/2031	Common Stock	85,000	\$0	85,000		D	

Explanation of Responses:

1. The option vests in four equal annual installments beginning on August 23, 2021.

/s/ Timothy C. Dec

08/23/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.